As you all know, I will be stepping down today after 5 deeply rewarding years as President and CEO of Teva. When I joined Teva, the company was already a generics powerhouse, with annual revenues of over $8 billion. The growth strategy we have implemented over these last 5 years has turned Teva into a larger, highly diversified global pharmaceutical company. As CEO, it has been extremely gratifying to lead Teva through this exciting period in its history. At a personal level, it has been a true privilege to work with Teva outstanding management team and employees to create a stronger and more balanced Teva.
Teva Pharmaceutical Industries Limited's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.